1. Scrip

Santen Fortifies Glaucoma Strategy With Sepetaprost Japan Filing

 
• By Lisa Takagi

The dual agonist of the FP and EP3 receptors has shown efficacy in a Japanese Phase III trial and completed its US Phase II study, which aligns with the Japanese firm’s global expansion strategy for glaucoma products.

Santen applied for sepetaprost's global first approval in Japan for glaucoma.
Santen seeks global first approval in Japan for sepetaprost in glaucoma. • Source: Shutterstock

Santen Pharmaceutical Co., Ltd. has filed for global first approval of sepetaprost (study code: STN1012600), its dual agonist of the FP and EP3 receptors, for glaucoma in Japan.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

More from Focus On Asia